NTRK1 and ovarian carcinoma: To date, encouraging results have been obtained with ovarian cancer trials incorporating VEGF-pathway inhibitors, the therapeutic antibody bevacizumab, and small molecule receptor tyrosine kinase inhibitors (TKIs)[27].